Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Alembic Pharma gets USFDA nod for Candesartan Cilexetil tablets

      Alembic Pharma gets USFDA nod for Candesartan Cilexetil tablets

      Medical Dialogues Bureau7 Dec 2018 9:15 AM IST
      New Delhi: Drug firm Alembic Pharma on Wednesday said it has received approval from the US health regulator for Candesartan Cilexetil tablets, used...
      AbbVie stops enrollment for a late-stage trial of Rova-T

      AbbVie stops enrollment for a late-stage trial of Rova-T

      Medical Dialogues Bureau7 Dec 2018 9:00 AM IST
      New Delhi: AbbVie Inc said on Wednesday it had halted enrollment for a late-stage trial of Rova-T as a second-line therapy for advanced small-cell...
      Novartis India Managing Director Milan Paleja quits

      Novartis India Managing Director Milan Paleja quits

      Medical Dialogues Bureau6 Dec 2018 10:05 AM IST
      New Delhi: Pharmaceutical major Novartis India recently announced that its Managing Director and Chairman, Milan Paleja has decided to resign from the...
      Apollo Hospitals pharmacy divest front-end biz,credit neutral

      Apollo Hospitals pharmacy divest front-end biz,credit neutral

      Medical Dialogues Bureau6 Dec 2018 9:45 AM IST
      New Delhi: Apollo Hospitals Enterprise' decision to divest its front-end pharmacy business to Apollo Pharmacy Ltd (APL) for cash consideration of Rs...
      Roches Tecentriq wins priority review in U.S for treatment of lung cancer

      Roche's Tecentriq wins priority review in U.S for treatment of lung cancer

      Medical Dialogues Bureau6 Dec 2018 9:30 AM IST
      ZURICH: Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small...
      Sanofi plans to reduce 670 jobs,efficiency to be affected

      Sanofi plans to reduce 670 jobs,efficiency to be affected

      Medical Dialogues Bureau6 Dec 2018 9:30 AM IST
      PARIS: French drugmaker Sanofi told unions on Wednesday it was planning to cut 670 jobs in France, a union representative told Reuters.The plan, which...
      Takeda shareholders nod to $59 billion Shire acquisition

      Takeda shareholders nod to $59 billion Shire acquisition

      Medical Dialogues Bureau6 Dec 2018 9:00 AM IST
      OSAKA: Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeovers of London-listed Shire, creating a global powerhouse with a...
      Indias medical value travel industry needs more measures: FICCI- EY Report

      India's medical value travel industry needs more measures: FICCI- EY Report

      Medical Dialogues Bureau5 Dec 2018 1:17 PM IST
      New Delhi: Steps such as infrastructure building, relaxing visa regulations and targeted outreach programmes would help in promoting medical value...
      Medtronic to pay whooping 51 million dollars to resolve U.S. medical device probes

      Medtronic to pay whooping 51 million dollars to resolve U.S. medical device probes

      Medical Dialogues Bureau5 Dec 2018 1:04 PM IST
      BOSTON - Medtronic Plc said on Tuesday it would pay $50.9 million to resolve U.S. Justice Department probes into how companies it later acquired...
      HUL, GSK Consumer shares rise 4 pc after boards approve merger

      HUL, GSK Consumer shares rise 4 pc after boards approve merger

      Medical Dialogues Bureau5 Dec 2018 9:57 AM IST
      New Delhi: Shares of Hindustan Unilever and Glaxo Smith Kline (GSK) Consumer Healthcare Monday surged 4 per cent on BSE after their boards approved...
      Novartis gene therapy could get FDA approval in May

      Novartis gene therapy could get FDA approval in May

      Medical Dialogues Bureau4 Dec 2018 9:40 AM IST
      ZURICH: Novartis's gene therapy for spinal muscular atrophy (SMA) could be approved in May 2019 after the U.S. Food and Drug Administration agreed to...
      Argenx and J&J subsidiary signs a deal to develop Cusatuzumab

      Argenx and J&J subsidiary signs a deal to develop Cusatuzumab

      Medical Dialogues Bureau4 Dec 2018 9:30 AM IST
      Netherlands: Netherland based biopharmaceutical company argenx said it has signed a deal with Cilag GmbH International, an affiliate of Johnson &...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok